190 related articles for article (PubMed ID: 26212543)
1. Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism.
Liu X; Lu Y; Guan X; Dong B; Chavan H; Wang J; Zhang Y; Krishnamurthy P; Li F
Biochem Pharmacol; 2015 Sep; 97(1):111-21. PubMed ID: 26212543
[TBL] [Abstract][Full Text] [Related]
2. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities.
Li X; Kamenecka TM; Cameron MD
Chem Res Toxicol; 2009 Oct; 22(10):1736-42. PubMed ID: 19803472
[TBL] [Abstract][Full Text] [Related]
3. CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism.
Li F; Lu J; Wang L; Ma X
Drug Metab Dispos; 2011 Mar; 39(3):394-401. PubMed ID: 21148252
[TBL] [Abstract][Full Text] [Related]
4. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
5. Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC-MS-Based Metabolomic Approaches.
Qin X; Wang Y; MacKenzie KR; Hakenjos JM; Chen S; Khalil SM; Jung SY; Young DW; Guo L; Li F
Chem Res Toxicol; 2023 Aug; 36(8):1427-1438. PubMed ID: 37531179
[TBL] [Abstract][Full Text] [Related]
6. Characterizing novel metabolic pathways of melatonin receptor agonist agomelatine using metabolomic approaches.
Liu X; Lu YF; Guan X; Zhao M; Wang J; Li F
Biochem Pharmacol; 2016 Jun; 109():70-82. PubMed ID: 27021842
[TBL] [Abstract][Full Text] [Related]
7. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
Li J; Zhao M; He P; Hidalgo M; Baker SD
Clin Cancer Res; 2007 Jun; 13(12):3731-7. PubMed ID: 17575239
[TBL] [Abstract][Full Text] [Related]
8. Reactive intermediates and bioactivation pathways characterization of avitinib by LC-MS/MS: In vitro metabolic investigation.
Attwa MW; Kadi AA; Abdelhameed AS
J Pharm Biomed Anal; 2019 Feb; 164():659-667. PubMed ID: 30472584
[TBL] [Abstract][Full Text] [Related]
9. Detection and characterization of olmutinib reactive metabolites by LC-MS/MS: Elucidation of bioactivation pathways.
Attwa MW; Kadi AA; Abdelhameed AS
J Sep Sci; 2020 Feb; 43(4):708-718. PubMed ID: 31788977
[TBL] [Abstract][Full Text] [Related]
10. In vitro bioactivation of a selective estrogen receptor modulator (2S,3R)-(+)-3-(3-hydroxyphenyl)-2-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-2,3-dihydro-1,4-benzoxathiin-6-ol (I) in liver microsomes: formation of adenine adducts.
Li Y; Doss GA; Li Y; Chen Q; Tang W; Zhang Z
Chem Res Toxicol; 2012 Nov; 25(11):2368-77. PubMed ID: 22998117
[TBL] [Abstract][Full Text] [Related]
11. CPY3A4-mediated α-hydroxyaldehyde formation in saquinavir metabolism.
Li F; Lu J; Ma X
Drug Metab Dispos; 2014 Feb; 42(2):213-20. PubMed ID: 24212380
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel Pathways in Idelalisib Metabolism and Bioactivation.
Zhu J; Wang P; Shehu AI; Lu J; Bi H; Ma X
Chem Res Toxicol; 2018 Jul; 31(7):548-555. PubMed ID: 29896955
[TBL] [Abstract][Full Text] [Related]
13. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
Li J; Karlsson MO; Brahmer J; Spitz A; Zhao M; Hidalgo M; Baker SD
J Natl Cancer Inst; 2006 Dec; 98(23):1714-23. PubMed ID: 17148773
[TBL] [Abstract][Full Text] [Related]
14. Investigation of Fenebrutinib Metabolism and Bioactivation Using MS
Alsibaee AM; Aljohar HI; Attwa MW; Abdelhameed AS; Kadi AA
Molecules; 2023 May; 28(10):. PubMed ID: 37241965
[TBL] [Abstract][Full Text] [Related]
15. Exacerbation of gefitinib-induced liver injury by glutathione reduction in mice.
Oda S; Miyazaki N; Tsuneyama K; Yokoi T
J Toxicol Sci; 2020; 45(8):493-502. PubMed ID: 32741899
[TBL] [Abstract][Full Text] [Related]
16. Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A.
Tang LWT; Wei W; Verma RK; Koh SK; Zhou L; Fan H; Chan ECY
Drug Metab Dispos; 2022 May; 50(5):529-540. PubMed ID: 35153194
[TBL] [Abstract][Full Text] [Related]
17. Belizatinib: Novel reactive intermediates and bioactivation pathways characterized by LC-MS/MS.
Attwa MW; Kadi AA; Darwish HW
J Pharm Biomed Anal; 2019 Jul; 171():132-147. PubMed ID: 30999224
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.
Towles JK; Clark RN; Wahlin MD; Uttamsingh V; Rettie AE; Jackson KD
Drug Metab Dispos; 2016 Oct; 44(10):1584-97. PubMed ID: 27450182
[TBL] [Abstract][Full Text] [Related]
19. Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha,beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme.
Kassahun K; Skordos K; McIntosh I; Slaughter D; Doss GA; Baillie TA; Yost GS
Chem Res Toxicol; 2005 Sep; 18(9):1427-37. PubMed ID: 16167835
[TBL] [Abstract][Full Text] [Related]
20. In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology.
Schulz-Utermoehl T; Spear M; Pollard CR; Pattison C; Rollison H; Sarda S; Ward M; Bushby N; Jordan A; Harrison M
Drug Metab Dispos; 2010 Oct; 38(10):1688-97. PubMed ID: 20634336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
